NRC — Preclinical in vivo Facility ### 📋 Eligible Entities - Biopharmaceutical companies (small, medium, and large) - Vaccine developers and manufacturers - Contract research organizations (CROs) requiring preclinical testing services - Academic institutions and research centers - Biotechnology firms developing biologics - Startups and spin-offs in the life sciences sector - Both Canadian and international clients can access this fee-for-service facility ### 💰 Funding Details - Model: Fee-for-service facility (not a traditional grant) - Cost Structure: Clients pay for services rendered based on testing scope and duration - No matching requirement from client organizations - Non-repayable: Fees are service payments, not loans - Flexible pricing: Costs vary by: - Type of biologics/vaccine being tested - Duration of in vivo studies - Complexity of safety and efficacy assessments - Animal model requirements and monitoring intensity ### 🛠️ Approved Expenses - In vivo animal testing (preclinical validation) - Biologics safety assessment and characterization - Vaccine design validation and efficacy testing - Pharmacokinetics and biodistribution studies - Toxicology evaluations in animal models - Immune response profiling and measurement - Product efficacy confirmation prior to human trials - Regulatory-compliant testing to support IND/clinical trial applications - Technical consultation from NRC scientific staff ### ⚠️ Conditions & Milestones - Regulatory compliance: All studies must meet Canadian and international preclinical standards (GLP where applicable) - Facility capacity: Access depends on available equipment and animal housing availability - Project timeline: Typical studies range from 3–12 months depending on complexity - Data ownership: Client retains intellectual property rights to results - Ethical oversight: All protocols must undergo animal care committee approval - Reporting requirements: Comprehensive final reports provided for regulatory submission - **Resource